Company intelligence / Profile preview

Microbiotics

Las Palmas de Gran Canaria, Canary Islands, Spainmicrobiotics.com.ng ↗

Ownership: Private
Development stage: Other

Overview

Health Microbiotics is developing new bioactive compounds derived from natural sources such as cyanobacteria and microalgae. The company has launched some nutraceutical products commercially while continuing R&D into pharmaceutical applications targeting diseases like breast, lung, or pancreatic cancer. Their approach emphasizes sustainability and safety by using ingredients already present in the human diet.

Therapeutic areas: OncologyOther
Modalities: Small moleculeNatural productBioactive compoundNutraceutical
Industry: Biotech

Partnerships

ICEX-Invest in Spain (funding/support)

Beyond the preview

Go deeper on Microbiotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbiotics.

Explore the full profile